Literature DB >> 10472097

Lumbosacral chordoma. Prognostic factors and treatment.

E Y Cheng1, R A Ozerdemoglu, E E Transfeldt, R C Thompson.   

Abstract

STUDY
DESIGN: Retrospective analysis.
OBJECTIVES: To analyze the prognostic factors in patients with chordomas, the success of various treatments, the diagnostic value of open versus needle biopsy, the neurologic impairment after sacral nerve resection, and the clinical presentation and site of origin. SUMMARY OF BACKGROUND DATA: Staging of chordomas has not been of much value, compared with other bone tumors, because for chordomas, grade is similar, metastasis is infrequent at presentation, and the prognostic significance of size is uncertain.
METHODS: A review of patients with chordoma from 1965 through 1996 found 23 cases (mean age of patients, 55 years). The mean follow-up was 84 months. Mean tumor size was 81 mm (range, 35-135 mm), location was lumbar (n = 6), S1 (n = 4), S2 (n = 3), S3 (n = 7), S4 (n = 2), and S5 (n = 1).
RESULTS: No tumors were found in the higher sacrum (S1-S2) alone, without involvement of the lower sacrum. Survival analysis at 5 years showed overall survival (OS) 86%, continuous disease-free survival (CDFS) 58%, and local recurrence-free survival (LRFS) 60%. The location of tumor, defined by highest level of involvement (lumbar vs. sacrum) was of prognostic significance for OS (P = 0.01; log-rank test), CDFS (P = 0.036), but not for LRFS (P = 0.189). Results of multivariate regression showed that location was significant for OS (P = 0.007), CDFS (P = 0.008), and LRFS (P = 0.001). For patients with positive margins (n = 16), initial radiation correlated with longer CDFS (P = 0.002; Mantel-Cox) and LRFS (P = 0.005, Mantel-Cox), but was not significant for OS (P = 0.41). For patients who received no radiation, a positive margin correlated with a shorter CDFS (P = 0.04), a trend to shorter LRFS (P = 0.08), but no difference in OS. Therefore, both a tumor-free margin and initial radiation correlated with a longer survival. No patients had urinary or bowel dysfunction when both S3 nerves were preserved. If one S3 nerve was preserved, 1 of 3 patients had partial urinary incontinence and 2 of 3 patients required bowel medications. If both S3 nerves were resected, all patients required intermittent urinary catheterization and bowel medications. If both S2 nerves were resected, there was complete urinary and bowel incontinence.
CONCLUSIONS: The highest level of tumor involvement was prognostically significant for OS, CDFS, and LRFS. Radiation was of value when complete excision was not achieved. Bilateral S3 nerve preservation is necessary to ensure retention of normal urinary and bowel function.

Entities:  

Mesh:

Year:  1999        PMID: 10472097     DOI: 10.1097/00007632-199908150-00004

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  55 in total

1.  Chordoma.

Authors:  Saad Khairi; Matthew G. Ewend
Journal:  Curr Treat Options Neurol       Date:  2002-03       Impact factor: 3.598

2.  Osseous metastases of chordoma: imaging and clinical findings.

Authors:  Connie Chang; Ivan Chebib; Martin Torriani; Miriam Bredella
Journal:  Skeletal Radiol       Date:  2017-01-07       Impact factor: 2.199

3.  Particle therapy using carbon ions or protons as a definitive therapy for patients with primary sacral chordoma.

Authors:  M Mima; Y Demizu; D Jin; N Hashimoto; M Takagi; K Terashima; O Fujii; Y Niwa; T Akagi; T Daimon; Y Hishikawa; M Abe; M Murakami; R Sasaki; N Fuwa
Journal:  Br J Radiol       Date:  2013-11-28       Impact factor: 3.039

4.  Spinal column chordoma: prognostic significance of clinical variables and T (brachyury) gene SNP rs2305089 for local recurrence and overall survival.

Authors:  Chetan Bettegowda; Stephen Yip; Sheng-Fu Larry Lo; Charles G Fisher; Stefano Boriani; Laurence D Rhines; Joanna Y Wang; Aron Lazary; Marco Gambarotti; Wei-Lien Wang; Alessandro Luzzati; Mark B Dekutoski; Mark H Bilsky; Dean Chou; Michael G Fehlings; Edward F McCarthy; Nasir A Quraishi; Jeremy J Reynolds; Daniel M Sciubba; Richard P Williams; Jean-Paul Wolinsky; Patricia L Zadnik; Ming Zhang; Niccole M Germscheid; Vasiliki Kalampoki; Peter Pal Varga; Ziya L Gokaslan
Journal:  Neuro Oncol       Date:  2017-03-01       Impact factor: 12.300

5.  Sacrococcygeal chordoma: MR imaging in 30 patients.

Authors:  Mi Sook Sung; Gyung Kyu Lee; Heung Sik Kang; Soon Tae Kwon; Jin Gyoon Park; Jin Suk Suh; Gil Ho Cho; Sung Moon Lee; Myung Hee Chung; Donald Resnick
Journal:  Skeletal Radiol       Date:  2004-10-08       Impact factor: 2.199

6.  Image-guided percutaneous lipiodol-pingyangmycin suspension injection therapy for sacral chordoma.

Authors:  Dexiao Huang; Yong Chen; Qingle Zeng; Renhua Wu; Yanhao Li
Journal:  Korean J Radiol       Date:  2013-08-30       Impact factor: 3.500

7.  "En bloc" resection of sacral chordomas by combined anterior and posterior surgical approach: a monocentric retrospective review about 29 cases.

Authors:  Arnaud Dubory; Gilles Missenard; Benoît Lambert; Charles Court
Journal:  Eur Spine J       Date:  2014-01-28       Impact factor: 3.134

8.  Recurrence and survival factors analysis of 171 cases of sacral chordoma in a single institute.

Authors:  Yongkun Yang; Xiaohui Niu; Yuan Li; Weifeng Liu; Hairong Xu
Journal:  Eur Spine J       Date:  2016-12-09       Impact factor: 3.134

9.  Combined anterior and posterior en bloc vertebrectomy for lumbar chordoma.

Authors:  Youn Young Jung; Ho Shin
Journal:  J Korean Neurosurg Soc       Date:  2009-04-30

10.  Sacral chordoma: can local recurrence after sacrectomy be predicted?

Authors:  S A Hanna; W J S Aston; T W R Briggs; S R Cannon; A Saifuddin
Journal:  Clin Orthop Relat Res       Date:  2008-06-27       Impact factor: 4.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.